← Issue №19/ week of Nov 8, 2026/Pancreas/Biliary

Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis.

From GI Signals issue №19: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Pancreas/Biliary rct · n=757 · Nov 5, 2026 · NEJM · IF 84.5

Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis.

New therapyacute pancreatitisbiomarkerepidemiology
Clinical takeawayPhase 3 evidence (SHASTA-3 and SHASTA-4, 757 adults) that lowering triglycerides with plozasiran 25 mg every 3 months lowers acute pancreatitis risk; check its approved indication before prescribing.
What it foundPlozasiran reduced acute pancreatitis risk to 1 per 100 patient-years vs 5 per 100 patient-years with placebo (rate ratio 0.22, P=0.008) and lowered triglycerides by 79-81% at 12 months. Adverse events occurred in 73% of patients in both plozasiran and placebo groups.
ContextTwo identically designed placebo-controlled trials; the pancreatitis result comes from a pooled analysis of adjudicated events. Adverse events occurred in 73% with plozasiran and with placebo.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Watts GF … SHASTA-3 and SHASTA-4 Study Groups · New England Journal of Medicine · IF 84.5 · PubMed ↗Permalink
← Read the whole of issue №19 Every paper GI Signals surfaces gets a page like this one. All issues